Aquestive Therapeutics, Inc. Common Stock (AQST) Stock Price

AQSTStock

$3.78−46.08%52W

Market Cap$474.43M

P/E—

PEG Ratio—

Div yield—

Beta1.53

AQST Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-18.82%

Price vs S&P 500 (4W)-19.60%

VGM Score44.23

Book Value / Share (Quarterly)$0.40

P/TBV (Annual)15.90x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.24%

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)-53.41%

Gross Margin (TTM)67.04%

Net Profit Margin (TTM)-144.63%

EPS (TTM)$-0.65

10-Day Avg Trading Volume2.24M

EPS Excl Extra (TTM)$-0.65

Revenue Growth (5Y)-0.58%

EPS (Annual)$-0.78

ROI (Annual)-107.16%

Gross Margin (Annual)58.35%

Net Profit Margin (5Y Avg)-106.64%

Cash / Share (Quarterly)$0.78

Revenue Growth QoQ (YoY)38.15%

ROA (Last FY)-52.23%

Revenue Growth TTM (YoY)22.56%

EBITD / Share (TTM)$-0.53

Operating Margin (TTM)-119.12%

Cash Flow / Share (Annual)$-0.43

P/B Ratio47.07x

P/B Ratio (Quarterly)15.59x

Net Income / Employee (Annual)$-570,000

EV / Revenue (TTM)9.55x

Net Interest Coverage (TTM)-10.98x

ROA (TTM)-52.39%

EPS Incl Extra (Annual)$-0.78

Current Ratio (Annual)3.14x

Quick Ratio (Quarterly)6.54x

3-Month Avg Trading Volume2.58M

52-Week Price Return-46.08%

Revenue / Employee (TTM)$367,900

Tangible BV / Share (Quarterly)$0.40

P/S Ratio (Annual)10.65x

Asset Turnover (Annual)0.28x

52-Week High$7.55

Operating Margin (5Y Avg)-85.84%

EPS Excl Extra (Annual)$-0.78

CapEx CAGR (5Y)1.57%

26-Week Price Return-8.92%

Quick Ratio (Annual)2.92x

13-Week Price Return-8.25%

Total Debt / Equity (Annual)4.68x

Current Ratio (Quarterly)7.19x

Enterprise Value$516.68M

Revenue / Share Growth (5Y)-21.10%

Asset Turnover (TTM)0.36x

Revenue / Employee (Annual)$303,000

Inventory Turnover (Annual)3.04x

Pretax Margin (Annual)-188.09%

Cash / Share (Annual)$0.99

3-Month Return Std Dev55.41%

Gross Margin (5Y Avg)63.19%

Net Income / Employee (TTM)$-532,200

ROE (Last FY)-608.93%

Net Interest Coverage (Annual)-7.70x

EPS Basic Excl Extra (Annual)$-0.78

P/FCF (TTM)25.88x

Receivables Turnover (TTM)5.25x

Total Debt / Equity (Quarterly)4.68x

EPS Incl Extra (TTM)$-0.65

Receivables Turnover (Annual)3.63x

ROI (TTM)-47.80%

P/S Ratio (TTM)8.77x

Pretax Margin (5Y Avg)-106.55%

Revenue / Share (Annual)$0.42

Tangible BV / Share (Annual)$0.40

Price vs S&P 500 (52W)-61.61%

Year-to-Date Return-41.49%

5-Day Price Return-21.41%

EPS Normalized (Annual)$-0.78

ROA (5Y Avg)-63.72%

Net Profit Margin (Annual)-188.09%

Month-to-Date Return-18.36%

Cash Flow / Share (TTM)$-0.17

EBITD / Share (Annual)$-0.66

Operating Margin (Annual)-159.50%

LT Debt / Equity (Annual)4.23x

ROI (5Y Avg)-141.26%

LT Debt / Equity (Quarterly)4.23x

EPS Basic Excl Extra (TTM)$-0.65

P/TBV (Quarterly)15.90x

P/B Ratio (Annual)15.59x

Inventory Turnover (TTM)2.30x

Pretax Margin (TTM)-144.63%

Book Value / Share (Annual)$0.40

Price vs S&P 500 (13W)-10.94%

Beta1.53x

P/FCF (Annual)126.52x

Revenue / Share (TTM)$0.43

ROE (TTM)-21.76%

52-Week Low$2.93

vGradeD

gGradeC

mGradeC

vgmGradeC

AQST Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.12	-$0.07	+45.67%(+$0.05)
Q1 2026	May 13, 2026	-$0.13	-$0.05	+64.69%(+$0.08)
Q4 2025	Mar 4, 2026	-$0.12	-$0.14	-18.08%(-$0.02)
Q3 2025	Nov 5, 2025	-$0.11	-$0.11	-4.18%(-$0.01)
Q2 2025	Aug 11, 2025	-$0.17	-$0.12	+32.27%(+$0.06)

AQST Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.20

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AQSTAquestive Therapeutics, Inc. Common Stock	D	C	C	8.8x	22.6%	67.0%	—	$3.78
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Aquestive Therapeutics, Inc. Common Stock

Aquestive Therapeutics is a specialty pharmaceutical company developing and commercializing products for central nervous system disorders and severe allergic reactions. The company markets four commercial products—Suboxone, Emylif, Ondif, and Sympazan—with pipeline candidates including Libervant Buccal Film and AQST-108. Revenue is primarily generated in the United States.

AQST Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.14

Revenue estimate$11.02M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

AQST Insider Transactions

SellSep 15, 2026
BARBER DANIEL R
Chief Executive Officer
Shares: 25,000Value: $120,488
SellSep 9, 2026
KORCZYNSKI SHERRY
Officer
Shares: 8,750Value: $45,675
SellAug 17, 2026
BARBER DANIEL R
Chief Executive Officer
Shares: 25,000Value: $107,168

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

TROXTRONOX LIMITED CL A ORDINARY SHARESIndustrial Chemicals
ETRAElectra Therapeutics, Inc. Common stockBiological Products
VALNValneva SE American Depositary SharesBiological Products
PROKProKidney Corp. Class A Ordinary SharesBiological Products
ENTXEntera Bio Ltd. Ordinary SharesBiological Products
LXFRLuxfer Holdings PLC Ordinary SharesIndustrial Chemicals
RGNXREGENXBIO Inc.Biological Products
ALLOAllogene Therapeutics, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$2.93

High$7.55